84 related articles for article (PubMed ID: 2405779)
1. [Ranimustine].
Masaoka T
Gan To Kagaku Ryoho; 1990 Feb; 17(2):301-7. PubMed ID: 2405779
[TBL] [Abstract][Full Text] [Related]
2. [Randomized controlled study of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU) in comparison with busulfan for chronic myelogenous leukemia].
Masaoka T; Kimura K; Miyazaki T; Hirota Y; Nakamura T; Yasunaga K; Ohkubo H; Okamoto Y; Fujitake H; Kitani T
Gan To Kagaku Ryoho; 1985 May; 12(5):1111-8. PubMed ID: 3888116
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera].
Nagai M; Tasaka T; Kamano H; Ohnishi H; Taoka T; Ikeda K; Kubota Y; Tanaka T; Irino S
Gan To Kagaku Ryoho; 1988 Dec; 15(12):3267-70. PubMed ID: 3196045
[TBL] [Abstract][Full Text] [Related]
4. [Phase II study of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU)].
Tanaka I; Kobayashi T; Shirakawa S; Ikeda Y; Kobayashi M; Yamagata K; Ohta K; Ohno R; Yamada H; Yamada K
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):493-8. PubMed ID: 3859248
[TBL] [Abstract][Full Text] [Related]
5. [Phase II study of a new nitrosourea derivative, MCNU, in tablet form. Takai Blood Cancer Study Group].
Kobayashi T; Tanaka I; Shirakawa S; Fujiwara Y; Hirota Y; Kobayashi M; Ohno R; Yamada H; Mitomo Y; Yamamoto M
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1079-85. PubMed ID: 3566304
[TBL] [Abstract][Full Text] [Related]
6. [Phase II study with methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU) in hematological malignancies].
Higuchi A; Miyazaki T; Sakurada K; Morioka M; Musashi M; Imamura M; Maekawa I; Saitoh H; Ohtani N; Kasai M
Gan To Kagaku Ryoho; 1985 Jun; 12(6):1253-9. PubMed ID: 3859250
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic effect of ranimustine(MCNU) on myeloproliferative disorder and chronic myelomonocytic leukemia].
Maeda S; Okabe M; Kurosawa M; Kunieda Y; Imamura M; Morioka M; Sakurada K; Miyazaki T; Sukegawa M
Gan To Kagaku Ryoho; 1991 Feb; 18(2):251-8. PubMed ID: 1992919
[TBL] [Abstract][Full Text] [Related]
9. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
10. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
[TBL] [Abstract][Full Text] [Related]
11. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
12. [Busulfan versus busulfan-interferon as maintenance therapy in chronic myeloid leukemia].
López Hernández MA; Flores-Chapa JD; Trueba Christy E; Borbolla Escoboza JR; Carrillo Rosales T
Rev Invest Clin; 1996; 48(4):281-7. PubMed ID: 8966391
[TBL] [Abstract][Full Text] [Related]
13. [Interferon in the eradication of the Philadelphia chromosome in chronic myeloid leukemia].
Arana-Trejo RM; Ovilla-Martínez R; Gómez-Morales E; Meillon-García L; Cervantes-Peredo A; González-Llaven J; Pizzuto-Chávez J; Kofman-Alfaro S
Rev Invest Clin; 1997; 49(3):209-14. PubMed ID: 9380976
[TBL] [Abstract][Full Text] [Related]
14. Interferon alpha in the treatment of chronic myelogenous leukemia.
Robak T
Arch Immunol Ther Exp (Warsz); 1998; 46(6):347-53. PubMed ID: 9883313
[TBL] [Abstract][Full Text] [Related]
15. A new nitrosourea derivative for the treatment of chronic myelogenous leukemia.
Hiraoka A; Masaoka T; Shibata H; Miyazaki T; Nakamura T; Yasunaga K; Kitani T; Yonezawa T; Kawagoe H; Horiuchi A
Leuk Res; 1988; 12(6):487-90. PubMed ID: 3043111
[TBL] [Abstract][Full Text] [Related]
16. [Phase II study of SM-108 (4-carbamoylimidazolium-5-olate) in hematological malignancies].
Kimura K; Yamada K; Uzuka Y; Masaoka T; Hirano M; Ohno R; Ogawa M
Gan To Kagaku Ryoho; 1989 Jan; 16(1):123-30. PubMed ID: 2643392
[TBL] [Abstract][Full Text] [Related]
17. [Phase II study on oral administration of MCNU (ranomustine) tablet. Hanshin Cooperative Study Group on Hematological Disorders].
Kanamaru A; Nagai K; Masaoka T; Shibata H; Kitani T; Taniguchi N; Horiuchi A; Tsubaki K; Kawagoe H; Hirata M
Gan To Kagaku Ryoho; 1986 May; 13(5):1915-20. PubMed ID: 3458432
[TBL] [Abstract][Full Text] [Related]
18. Detection of bcr/abl mRNA in a case of chronic myelogenous leukemia in long-term remission: CML or sensitivity of detection?
Anguita E; Villegas A; Díaz-Mediavilla J; González FA; del Potro E; Espinós D
Haematologica; 1998 Aug; 83(8):744-7. PubMed ID: 9793259
[TBL] [Abstract][Full Text] [Related]
19. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
20. [Therapy of chronic myelogenous leukemia in 2004].
Hochhaus A; Berger U; Hehlmann R
Dtsch Med Wochenschr; 2004 Oct; 129(40):2122-7. PubMed ID: 15455305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
